Navigation Links
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
Date:8/7/2009

this kind of device on any organ and the ability to deliver medication to the affected organ, could be a huge advance in how we currently treat cancer," Dr. Murphree said. This work is done in conjunction with Ricardo Carvalho, M.D., Ph.D. and the company 3T Ophthalmics which is developing the drug delivery system.

The episcleral drug reservoir is inserted under the thin, filmy conjunctiva, or covering of the eyeball, to the sclera -- the fibrous, protective outer layer of the eye. The tiny cup administers the drug slowly by passive diffusion through the sclera, where it reaches the retina and vitreous. The device is so small the patient should feel little or no discomfort and it does not hinder normal vision.

Currently, drugs for most retinal diseases are delivered either through an I.V. drip (i.e. systemically) or by an injection into the eyeball (i.e. intravitreal), both of which pose risks for the patient.

For example, chemotherapy for retinoblastoma, a cancer affecting one in 15,000 children, must now be given intravenously. This requires relatively large doses of the drug are needed to achieve a therapeutic concentration in the retina. The chemotherapy destroys the bone marrow and depresses the child's immune system, often leading to secondary infections.

Intravitreal injections using a syringe, often used to treat age-related macular degeneration, require frequent out-patient visits and can lead to vitreous hemorrhage and retinal detachment. Eye drops are also generally ineffective for retinal diseases because most medications are washed away or diluted before they have a chance to reach the retina, located at the back of the eye close to the brain.

"When we administer chemotherapy to an infant for retinoblastoma at The Vision Center, it is expensive and puts a great strain on the family, especially if they are from another state. Our preliminary research shows that
'/>"/>

SOURCE Children's Hospital Los Angeles
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
2. Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
3. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
4. Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients
5. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
6. Back to Normal: Surgery Improves Outcomes for Spine Patients
7. New Research Shows Nutrition 21s Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings
8. New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
9. Program Improves Language Skills in Deaf, Hard of Hearing
10. Brain Training Improves Memory and Attention and the Effects Last
11. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 WuXi PharmaTech (Cayman) ... and technology platform company serving the pharmaceutical, ... small-molecule process development and manufacturing subsidiary Shanghai ... first approval from the Japan PMDA for ... a branded commercial drug in July. STA ...
(Date:8/27/2015)... NEWARK, N.J. , Aug. 27, 2015  Symbiomix ... Phase 3 clinical study, the second pivotal trial of ... the treatment of bacterial vaginosis (BV). Earlier this year ... for SYM-1219. Symbiomix expects to finish this second pivotal ... a New Drug Application (NDA) filing with the U.S. ...
(Date:8/27/2015)... 27, 2015 The global ... USD 3.96 billion by 2022, according to a new ... chronic venous disorders such as deep vein thrombosis, leg ... as the key driver.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) ... are also expected to boost market growth over the ...
Breaking Medicine Technology:WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 3Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... 4, 2011 PRO-DEX, INC. (Nasdaq: PDEX ) ... of the Company,s fiscal 2011 third quarter financial results. ... over the internet on Tuesday, May 10, 2011 at 9:30 ... accessed by visiting the Company,s website at www.pro-dex.com . ...
... 4, 2011 Cardiogenesis Corporation (OTCQB: CGCP), a leading developer ... artery disease, today reported financial results for its first quarter ... quarter of 2011 was $3,053,000, a 6% decrease from prior ... net loss of $433,000, or $0.01 per basic and diluted ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Third Quarter Financial Results Conference Call and Webcast 2Cardiogenesis Reports First Quarter 2011 Results 2Cardiogenesis Reports First Quarter 2011 Results 3Cardiogenesis Reports First Quarter 2011 Results 4Cardiogenesis Reports First Quarter 2011 Results 5Cardiogenesis Reports First Quarter 2011 Results 6
(Date:8/27/2015)... , ... August 27, 2015 , ... According to an ... Conference on Abdominal Wall Hernia Surgery involved many conversations between hernia experts surrounding the ... there, the article notes that many different experts have different ideas about which is ...
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. ... Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, ... outlets as health authorities, and will present a two part seminar entitled, “How to ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, ... second year as sponsor of the “Music With A Mission” benefit concert. For the ... music education programs in the underfunded school districts of Mendon and neighboring town, Quincy, ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: